---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011110"
form_type: "8-K"
ticker: "DXR"
cik: "0000027367"
company_name: "DAXOR CORP"
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:49:27.628220+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Daxor acquires worldwide rights to Volumex, Megatope, and Glofil from Iso-Tex Diagnostics

## Summary
- No upfront payment; seller-financed with monthly installments starting after manufacturing transition in 6–9 months.
- Deal expected to be immediately accretive and cash flow positive due to higher margins from in-house production.
- Glofil (GFR diagnostic) adds recurring revenue stream and cross-selling opportunity to existing hospital customers.
- Volumex and Megatope radiopharmaceuticals for blood volume analysis will be produced at Daxor's Oak Ridge facility.
- Transaction subject to customary closing conditions including applicable regulatory approvals.

## SEC filing metadata
- accession: 0001493152-24-011110
- form_type: 8-K
- ticker: DXR
- cik: 0000027367
- company_name: DAXOR CORP
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/27367/000149315224011110/0001493152-24-011110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/27367/000149315224011110/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011110
- JSON: https://secwatch.observer/filing/0001493152-24-011110.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.